MeiraGTx Holdings plc

Equities

MGTX

KYG596651029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.8 ^USD	+1.91%		-5.70%	-31.62%

Apr. 16	MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board	CI
Mar. 14	MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

MeiraGTx Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 14, 2023 at 08:00 am EST

MeiraGTx Holdings plc reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 44.3 million compared to USD 37.28 million a year ago. Basic loss per share from continuing operations was USD 0.74 compared to USD 0.83 a year ago.
For the nine months, net loss was USD 104.24 million compared to USD 102.3 million a year ago. Basic loss per share from continuing operations was USD 1.91 compared to USD 2.29 a year ago.

Latest news about MeiraGTx Holdings plc

MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board	Apr. 16	CI
MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Who are OpenAI's new board members?	Mar. 11	RE
MeiraGTx to Receive $50 Million Milestone Payment from J&J's Janssen Under Bota-Vec Deal	Feb. 13	MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 21	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Dec. 21	MT
MeiraGTx Holdings Shares Rise on Sale of Remaining Bota-vec Interests to Janssen Pharmaceuticals for Up to $415 Million	Dec. 21	MT
Janssen Pharmaceuticals, Inc. agreed to acquire Assets of MeiraGTx Holdings plc from MeiraGTx Holdings plc for approximately $130 million.	Dec. 20	CI
MeiraGTx Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
MeiraGT Receives $30 Million Strategic Investment from Sanofi; to Seek Further Strategic Opportunities	23-10-30	MT
MeiraGTx Gets $30 Million Investment From Sanofi	23-10-30	DJ
Top Premarket Gainers	23-10-30	MT
MeiraGTx Holdings plc announced that it has received $30 million in funding from Sanofi Foreign Participations B.V.	23-10-29	CI
MeiraGTx Holdings plc Announces an Oral Presentation and Eight Posters At the European Society of Gene and Cell Therapy 2023 Annual Congress	23-10-24	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
RBC Cuts Price Target on MeiraGTx Holdings to $11 From $13, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
MeiraGTx Holdings plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
MeiraGTx Gets Irish Regulator's Authorization for Quality Control Testing at Manufacturing Facility	23-07-19	MT
MeiraGTx Says Treatment Candidate for Dry Mouth Improved Symptoms in Phase 1 Trial	23-06-27	MT
Transcript : MeiraGTx Holdings plc - Special Call	23-06-27
MeiraGTx Holdings plc Announces Positive Clinical Data from the AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia	23-06-27	CI
MeiraGTx Holdings plc to Present 12-Month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study	23-06-22	CI
Piper Sandler Adjusts Price Target on MeiraGTx Holdings to $25 From $26, Keeps Overweight Rating	23-05-12	MT
RBC Cuts Price Target on MeiraGTx Holdings to $13 From $15, Maintains Outperform, Speculative Risk	23-05-12	MT

Chart MeiraGTx Holdings plc

Duration

Period

More charts

Company Profile

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for MeiraGTx Holdings plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.8 USD

Average target price

21.6 USD

Spread / Average Target

+350.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEIRAGTX HOLDINGS PLC	-31.62%	309M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs